ArticleBMJ case reports2015
Tocilizumab for refractory organising pneumonia associated with Sjögren's disease.
Article in BMJ case reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Composition and regulation of the immune microenvironment of salivary gland in Sjögren's syndrome.Frontiers in immunology · 2022Pooled it
- The Th17/Treg axis: a key to understanding and treating autoimmune disorders.Open life sciences · 2026Article
- How I diagnose and treat organizing pneumonia in hematopoietic cell transplant recipients.Blood · 2024Review
- Investigative biological therapies for primary Sjögren's syndrome.Archives of medical science : AMS · 2024Article
- Concurrent remission of lymphoma and Sjögren's disease following anti-CD19 chimeric antigen receptor-T cell therapy for diffuse large B-cell lymphoma: a case report.Frontiers in immunology · 2023Article
- Organizing pneumonia as presenting feature of primary Sjögren's syndrome: A case report.Respiratory medicine case reports · 2023Article
- Biologic therapy in Sjögren's syndrome.Clinical rheumatology · 2021Review
- Diagnosis and management of lung involvement in systemic lupus erythematosus and Sjögren's syndrome: a literature review.Therapeutic advances in musculoskeletal disease · 2021Review
- Shared Pathogenetic Features Between Common Variable Immunodeficiency and Sjögren's Syndrome: Clues for a Personalized Medicine.Frontiers in immunology · 2021Review
- Biological Therapy in Primary Sjögren's Syndrome: Effect on Salivary Gland Function and Inflammation.Frontiers in medicine · 2021Review
- Innate Immunity and Biological Therapies for the Treatment of Sjögren's Syndrome.International journal of molecular sciences · 2020Review
- Therapeutic Options for the Treatment of Interstitial Lung Disease Related to Connective Tissue Diseases. A Narrative Review.Journal of clinical medicine · 2020Review
- Surgical management of organizing pneumonia: a retrospective study of 24 cases in a single Centre.Journal of cardiothoracic surgery · 2019Article
- The Two-Faced Cytokine IL-6 in Host Defense and Diseases.International journal of molecular sciences · 2018Review
- Treatment of primary Sjögren syndrome.Nature reviews. Rheumatology · 2016Review
- Pulmonary manifestations of Sjögren's syndrome.European respiratory review : an official journal of the European Respiratory Society · 2016Review
- Systematic Review of Systemic Corticosteroids for Treatment of Organizing Pneumonia.Open respiratory archivesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung involvement in primary Sjögren syndrome occurs in approximately 10-20% of patients. Tocilizumab, an anti-interleukin-6 receptor antibody, has demonstrated efficacy and safety in small series of systemic sclerosis, and systemic lupus erythematosus, but its effect on interstitial lung manifestations of connective tissue diseases is not well known. We report the use of tocilizumab in a refractory organising pneumonia associated with Sjögren's disease. Our observation suggests that tocilizumab could be an alternative therapeutic in refractory organising pneumonia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.